The popular type 2 diabetes drug dulaglutide (Trulicity), botulinum toxin (Botox), and drugs to treat psoriatic arthritis, prostate cancer, and breast cancer are among the 15 drugs that the Centers ...

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 ...

Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump and the Centers for Medicare & Medicaid Services (CMS) recently announced the 15 drugs whose prices they ...

Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...

The US plans to slash the price it pays for Botox and diabetes drug Trulicity, the latest medicines to be targeted under legislation that’s expected to save the government more than $200 billion over ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Trump ...

The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and ...

The Centers for Medicare and Medicaid Services (CMS) have announced the next 15 drugs whose prices will be negotiated as part of the third round of Medicare negotiations. This latest round of ...

The new cycle of Medicare drug price negotiations includes 15 high-cost drugs, with some covered under Medicare Part B for the first time. The negotiations, part of the Inflation Reduction Act, aim to ...

The federal government announced the next 15 medicines for which it will seek price reductions with the help of Medicare’s new negotiating power, including the breast cancer drugs Kisqali and Verzenio ...